Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy

What Was Tested

This randomized controlled trial paper looks at Teriparatide in the context of osteoporosis and bone density.

The purpose of this manuscript is to report on bone mineral density and vertebral fracture incidence during a 42-month observation period, from the baseline of the previously reported treatment study in men [1] through 30 months of posttreatment follow-up.

Why It Was Studied

Further, there is limited information on the effect of withdrawal of teriparatide.

Who Took Part

According to the abstract, 279 men were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, men only.

Three hundred fifty-five men who were treated with once-daily self-injections of either placebo or 20 or 40 microg of teriparatide participated in the follow-up study.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Teriparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some men received a placebo instead of Teriparatide, giving a reference point.

What Was Measured

PubMed files the paper under topics including Bone Density, Hip Joint, Lumbar Vertebrae, Osteoporosis, Spinal Fractures and Teriparatide.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Teriparatide in 279 men in people with osteoporosis and bone density.

The publication is from 2005 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, Osteoporosis and bone density research.